Besides the normal, physiological processes, SATB1 was found to be overexpressed in numerous malignancies, including lymphomas, breast, colorectal, prostate, liver, bladder and ovarian cancers, osteosarcoma and glioma [17,35,36,37,38,39,40,41]. Here, SATB1 is linked to ovarian cancer.